Gabather AB (publ) (GABA.ST)
SEK 0.4
(-3.61%)
SEK 0.4
(-3.61%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -9.47 Million SEK | -10.79% |
| 2022 | -8.55 Million SEK | 49.67% |
| 2021 | -16.99 Million SEK | -15.19% |
| 2020 | -14.75 Million SEK | -3.34% |
| 2019 | -14.27 Million SEK | 29.65% |
| 2018 | -20.28 Million SEK | -104.17% |
| 2017 | -9.93 Million SEK | -25.88% |
| 2016 | -7.89 Million SEK | -32.33% |
| 2015 | -5.96 Million SEK | -130.68% |
| 2014 | -2.58 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -3.18 Million SEK | -7.34% |
| 2024 Q2 | -1.72 Million SEK | 45.92% |
| 2023 Q3 | -2.82 Million SEK | -73.18% |
| 2023 Q2 | -1.63 Million SEK | 20.03% |
| 2023 Q1 | -2.04 Million SEK | 17.06% |
| 2023 Q4 | -2.97 Million SEK | -5.02% |
| 2023 FY | -9.47 Million SEK | -10.84% |
| 2022 Q4 | -2.46 Million SEK | -18.48% |
| 2022 Q1 | -1.95 Million SEK | 65.02% |
| 2022 Q2 | -2.05 Million SEK | -5.54% |
| 2022 Q3 | -2.07 Million SEK | -0.97% |
| 2022 FY | -8.55 Million SEK | 49.67% |
| 2021 Q4 | -5.57 Million SEK | -47.46% |
| 2021 FY | -16.99 Million SEK | -15.19% |
| 2021 Q1 | -3.45 Million SEK | -3.16% |
| 2021 Q2 | -4.18 Million SEK | -21.04% |
| 2021 Q3 | -3.78 Million SEK | 9.63% |
| 2020 Q4 | -3.35 Million SEK | 24.46% |
| 2020 FY | -14.75 Million SEK | -3.34% |
| 2020 Q3 | -4.43 Million SEK | -67.61% |
| 2020 Q1 | -4.32 Million SEK | -18.03% |
| 2020 Q2 | -2.64 Million SEK | 38.75% |
| 2019 Q2 | -4.16 Million SEK | -12.09% |
| 2019 Q4 | -3.66 Million SEK | -33.83% |
| 2019 Q3 | -2.73 Million SEK | 34.32% |
| 2019 FY | -14.27 Million SEK | 29.65% |
| 2019 Q1 | -3.71 Million SEK | 9.06% |
| 2018 Q3 | -5.16 Million SEK | 15.65% |
| 2018 Q4 | -4.08 Million SEK | 20.88% |
| 2018 FY | -20.28 Million SEK | -104.17% |
| 2018 Q1 | -4.71 Million SEK | -45.17% |
| 2018 Q2 | -6.12 Million SEK | -29.85% |
| 2017 Q4 | -3.24 Million SEK | -82.73% |
| 2017 Q2 | -2.58 Million SEK | -10.59% |
| 2017 Q1 | -2.33 Million SEK | -4.22% |
| 2017 FY | -9.93 Million SEK | -25.88% |
| 2017 Q3 | -1.77 Million SEK | 31.12% |
| 2016 Q1 | -1.62 Million SEK | -16.04% |
| 2016 FY | -7.89 Million SEK | -32.33% |
| 2016 Q2 | -2.23 Million SEK | -37.45% |
| 2016 Q4 | -2.23 Million SEK | -25.19% |
| 2016 Q3 | -1.78 Million SEK | 20.14% |
| 2015 Q2 | -2.06 Million SEK | -70.53% |
| 2015 Q3 | -1.28 Million SEK | 37.77% |
| 2015 Q4 | -1.4 Million SEK | -9.5% |
| 2015 FY | -5.96 Million SEK | -130.68% |
| 2015 Q1 | -1.2 Million SEK | -29.47% |
| 2014 Q2 | -9000.00 SEK | 0.0% |
| 2014 Q4 | -933 Thousand SEK | -19.16% |
| 2014 FY | -2.58 Million SEK | 0.0% |
| 2014 Q3 | -783 Thousand SEK | -8600.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AcuCort AB | -13.24 Million SEK | 28.493% |
| AlzeCure Pharma AB (publ) | -38.26 Million SEK | 75.239% |
| BioGaia AB (publ) | 440.9 Million SEK | 102.149% |
| Enzymatica AB (publ) | -48.06 Million SEK | 80.288% |
| Enorama Pharma AB (publ) | -41.83 Million SEK | 77.356% |
| Klaria Pharma Holding AB (publ.) | -14.68 Million SEK | 35.463% |
| Moberg Pharma AB (publ) | -27.46 Million SEK | 65.503% |
| Nanexa AB (publ) | -76.62 Million SEK | 87.636% |
| Newbury Pharmaceuticals AB (publ) | -14.07 Million SEK | 32.704% |
| ODI Pharma AB | -1.34 Million SEK | -606.151% |
| Orexo AB (publ) | -109.5 Million SEK | 91.348% |
| Probi AB (publ) | 11.32 Million SEK | 183.693% |
| Swedencare AB (publ) | 173.2 Million SEK | 105.47% |
| Swedish Orphan Biovitrum AB (publ) | 4.65 Billion SEK | 100.203% |
| Toleranzia AB | -7.89 Million SEK | -20.061% |
| Vivesto AB | -356.71 Million SEK | 97.344% |